# SAB Biotherapeutics

Type: Company (SABS)

Source: GetYourBrief — https://getyourbrief.com/entity/sab-biotherapeutics
Canonical HTML page: https://getyourbrief.com/entity/sab-biotherapeutics

## Timeline

- **2026-03-17**: Wall Street Zen Downgrade — SABS and SSSS both receive Sell ratings from Wall Street Zen.
- **2025-Q4**: SAB-142 Clinical Progress — SAB Biotherapeutics continues enrollment for its Phase 1/2 trial in Type 1 Diabetes.
- **2025**: Strategic Pivot — Company shifts focus from infectious diseases to immunology and chronic conditions.

## Recent coverage (2 stories, network-wide)

### Wall Street Zen Downgrades SAB Biotherapeutics and SURO Capital to Sell
2026-03-17 06:53:16 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has issued 'Sell' ratings for both SAB Biotherapeutics and SURO Capital, signaling a shift in sentiment for high-risk biotech and venture-backed assets. These downgrades reflect growing analyst caution regarding clinical-stage development timelines and private equity valuation gaps in the 2026 market environment.
Full story: https://getfinancebrief.com/story/sab-biotherapeutics-suro-capital-downgrade-wall-street-zen

### SAB Biotherapeutics Downgraded to Sell Amid Shifting Biotech Sentiment
2026-03-17 06:51:38 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen has downgraded SAB Biotherapeutics (SABS) and its investor SURO Capital (SSSS) to Sell ratings. The move signals increasing caution regarding SAB's clinical-stage polyclonal antibody platform and the broader venture-backed biotech ecosystem.
Full story: https://getbiobrief.com/story/sab-biotherapeutics-downgraded-sell-wall-street-zen

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.